Narrative ReviewMolecular autism2020

Emerging proteomic approaches to identify the underlying pathophysiology of neurodevelopmental and neurodegenerative disorders.

Nadeem Murtaza, Jarryll Uy, Karun K Singh

PMID 32317014

WHAT IT FOUND

This narrative review describes laboratory proteomic methods for studying autism spectrum disorder.

It does not report a clinical study or patient outcomes, so there is no finding to change practice.

What this paper is

This is a narrative review of proteomic methods used to study autism spectrum disorder and related neurodevelopmental or neurodegenerative disorders. It describes laboratory approaches such as mass spectrometry, post-mortem brain analysis, blood or urine biomarker work, and induced pluripotent stem cell models, and it cites other studies. It does not test an intervention in patients or report patient outcomes, so there is no clinical finding here to act on.

The easy way to misread this

Do not read this review as evidence that proteomic testing is available for diagnosing or managing autism spectrum disorder in patients. The paper summarizes laboratory methods and cited studies, not a clinical trial or validated patient test.

Read it on PubMed →


The study

Certainty of evidence
Low

Browse

    Cite

    Nadeem Murtaza, Jarryll Uy, Karun K Singh Emerging proteomic approaches to identify the underlying pathophysiology of neurodevelopmental and neurodegenerative disorders. Molecular autism. 2020.

    Read the original